DUSC public release documents by meeting
Page last updated: 22 November 2024
June 2024
- Analysis of brentuximab vedotin for cutaneous and peripheral T-cell lymphoma, June 2024
- Analysis of galcanezumab and fremanezumab for chronic migraine, June 2024
- Analysis of semaglutide for Type 2 diabetes mellitus, June 2024
February 2024
- Analysis of nivolumab and ipilimumab for mesothelioma, February 2024
- Analysis of dupilumab for asthma, February 2024
- Analysis of romosozumab for osteoporosis, February 2024
- Analysis of progesterone for preterm birth, February 2024
September 2023
- Analysis of dupilumab for severe atopic dermatitis, September 2023
- Analysis of Pharmaceutical Benefits Scheme (PBS) and Repatriation PBS (R/PBS) listed medicines used in the management of attention deficit hyperactivity disorder, September 2023
- Analysis of apremilast for severe chronic plaque psoriasis, September 2023
- Analysis of venetoclax for first-line treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma, September 2023
June 2023
- Analysis of olaparib for ovarian, fallopian tube and primary peritoneal cancer, June 2023
- Analysis of impact of regulatory reforms on utilisation of opioids, June 2023
- Analysis of omalizumab for chronic spontaneous urticaria, June 2023
February 2023
September 2022
- Analysis of medicines for the treatment of non-small cell lung cancer, including a predicted versus actual analysis of durvalumab, September 2022
- Medicines for the treatment of type 2 diabetes, September 2022
- Nivolumab as adjuvant treatment of melanoma: 24 month predicted versus actual analysis and melanoma market review, September 2022
- Atezolizumab for extensive-stage small cell lung cancer: analysis of predicted versus actual utilisation, September 2022
June 2022
- Analysis of proton pump inhibitor (PPI) medicines used in the management of gastrointestinal acid related disorders, June 2022
- Teduglutide for Short Bowel Syndrome: 24 month predicted versus actual analysis, June 2022
February 2022
- Analysis of medicines for the treatment of locally advanced and metastatic breast cancer: including a 24 month predicted versus actual analysis of palbociclib, February 2022
- Avelumab for Merkel cell carcinoma: 24 month predicted versus actual analysis, February 2022
- Cladribine for relapsing remitting multiple sclerosis: predicted versus actual analysis, February 2022
October 2021
- Golimumab for non-radiographic axial spondyloarthritis, October 2021
- Nivolumab plus Ipilimumab for first-line Stage IV clear cell variant renal cell carcinoma, October 2021
- Pembrolizumab for locally advanced or metastatic urothelial carcinoma, October 2021
- Bictegravir+emtricitabine+tenofovir alafenamide and dolutegravir+rilpivirine for HIV, October 2021
- NPS analysis on HIV and PrEP medications using MedicineInsight and PBS data, October 2021
- Tolvaptan for autosomal dominant polycystic kidney disease
June 2021
- Evolocumab for heterozygous familial hypercholesterolaemia, June 2021
- Guanfacine for attention deficit hyperactivity disorder, June 2021
- Somatropin for growth hormone therapy, June 2021
February 2021
- Ocular lubricants utilisation analysis PBS data, February 2021
- Ocular lubricants utilisation analysis MedicineInsight data, February 2021
- Nusinersen for spinal muscular atrophy, February 2021
October 2020
- Adrenaline autoinjectors utilisation analysis, October 2020
- Alectinib for non-small cell lung cancer, October 2020
- Denosumab for osteoporosis, October 2020
- Eculizumab for atypical haemolytic uremic syndrome (aHUS), October 2020
- Ibrutinib for chronic lymphocytic leaukaemia/ small lymphocytic lymphoma, October 2020
- Ocrelizumab for relapsing-remitting multiple sclerosis, October 2020
June 2020
- Nivolumab for non-small cell lung cancer, June 2020
- Nivolumab for renal cell carcinoma, June 2020
- Omalizumab for chronic spontaneous urticaria, June 2020
February 2020
- Alemtuzumab for relapsing remitting multiple sclerosis: 24 month predicted versus actual analysis, February 2020
- Idiopathic pulmonary fibrosis: 24 month predicted versus actual analysis, February 2020
- Opioid Analgesics, February 2020
- Testosterone, February 2020
October 2019
- Lenalidomide for newly diagnosed multiple myeloma, October 2019
- Tyrosine kinase inhibitors for chronic myeloid leukaemia, October 2019
- Biologics for uncontrolled severe allergic and eosinophilic asthma, October 2019
- Evolocumab for homozygous familial hypercholesterolaemia, October 2019
June 2019
- Armodafinil, 24 month predicted versus actual analysis, June 2019
- GnRH Agonists, Utilisation analysis, June 2019
- Sapropterin, 24 month predicted versus actual analysis, June 2019
February 2019
- Bendamustine for the treatment of lymphoma: 24 month predicted versus actual analysis, February 2019
- Eculizumab for aHUS: utilisation update, February 2019
September 2018
- Bevacizumab for epithelial ovarian, fallopian tube or primary peritoneal cancer 24 months review, September 2018
- Direct acting antiviral medicines for the treatment of chronic hepatitis C, September 2018
- Febuxostat for gout 24 months review, September 2018
- Ruxolitinib for myelofibrosis 24 months review, September 2018
May 2018
- Attention Deficit Hyperactivity Disorder, May 2018
- Botulinum toxin for spasticity and dystonia, May 2018
- Ranibizumab and aflibercept: analysis of use for AMD, DMO and RVO, May 2018
- Medicines for the treatment of melanoma, May 2018
- Posaconazole 24 month review, May 2018
February 2018
- Metastatic colorectal cancer, February 2018
- Medicines for HER2 positive metastatic breast cancer, February 2018
- Ivacaftor for cystic fibrosis, February 2018
September 2017
- 5-aminosalicylic acids for ulcerative colitis
- Eculizumab for aHUS
- Everolimus and sunitinib for pNET
- Lenalidomide for myelodysplastic syndrome
- Nab-paclitaxel for pancreatic cancer
- Multiple myeloma
June 2017
- Botulinum toxin for chronic migraine, June 2017
- Crohn disease, June 2017
- Ulcerative colitis, June 2017
February 2017
- Erlotinib and gefitinib for non-small cell lung cancer 24 month review, February 2017
- Everolimus for breast cancer 24 month review, February 2017
- Everolimus for tuberous sclerosis complex 24 month review, February 2017
- Ferric carboxymaltose 24 month review, February 2017
- Imatinib for gastrointestinal stromal tumour 24 month review, February 2017
- Medicines for diabetes, February 2017
September 2016
- Antifungals for systemic use, September 2016
- Antipsychotic medicines and 25 mg quetiapine 24 month review, September 2016
- Mifepristone and misoprostol, September 2016
- Medicines for osteoporosis, September 2016
- Rifaximin 24 month review, September 2016
- Testosterone, September 2016
June 2016
- bDMARDs for ankylosing spondylitis, June 2016
- Medicines for glaucoma, June 2016
- Novel oral anticoagulants for non-valvular atrial fibrillation, June 2016
- Oral medicines for metastatic prostate cancer, June 2016
February 2016
- Medicines for Alzheimer disease, February 2016
- bDMARDs for ankylosing spondylitis, February 2016
- bDMARDs for psoriatic arthritis, February 2016
- Smoking cessation therapy, February 2016
- Ticagrelor, February 2016
October 2015
- Alprazolam, October 2015
- bDMARDS for psoriatic arthritis, October 2015
- Ipilimumab and dabrafenib for unresectable melanoma, October 2015
- Multiple Sclerosis, October 2015
- Nutritional products, October 2015
- Pregabalin 24 month review, October 2015
June 2015
- Aflibercept and ranibizumab for age-related macular degeneration, June 2015 1
- Attention deficit hyperactivity disorder, June 2015
- Dutasteride and dutasteride with tamsulosin for benign prostatic hyperplasia, June 2015
- Icatibant for hereditary angioedema, June 2015
- Romiplostim and eltrombopag for idiopathic thrombocytopenic purpura, June 2015
February 2015
- Antibiotics, October 2014 and February 2015
- bDMARDs for Crohn's disease, February 2015
- Hepatitis B, February 2015
- Pulmonary Arterial hypertension, February 2015
October 2014
- Antibiotics, October 2014 and February 2015
- Cystic fibrosis: tobramycin inhalation 24 month review, October 2014
- Cystic fibrosis: dornase and mannitol, October 2014
- Exenatide, October 2014
- Ezetimibe with simvastatin, October 2014
- Novel oral anticoagulants for deep vein thrombosis, pulmonary embolism and recurrent venous thromboembolism, October 2014
- Opioids, October 2014
- Pregabalin 12 month review, October 2014
June 2014
- Bone metastases, June 2014
- bDMARDs for chronic plaque psoriasis, June 2014
- Ocular lubricants, June 2014
- Omalizumab 24 month review, June 2014
- Pazopanib and sunitinib for renal cell carcinoma, June 2014
February 2014
- Iron chelating agents, February 2014
- Tyrosine kinase inhibitors for the treatment of chronic myeloid leukaemia, February 2014
June 2013
- Antipsychotics in children and adolescents, February 2013 & June 2013
- Antipsychotics in the middle aged, February 2013 & June 2013
February 2013
- Antipsychotics in children and adolescents, February 2013 & June 2013
- Antipsychotics in the middle aged, February 2013 & June 2013
- Type 2 diabetes, October 2012 and February 2013
October 2013
- Testosterone, October 2012
- Type 2 diabetes, October 2012 and February 2013
-
Suggested citation:
[1]Department of Health. Age Related Macular Degeneration: utilisation analysis. Canberra: Department of Health; 2015. Available from http://www.pbs.gov.au/info/industry/listing/participants/public-release-docs/aflibercept-ranibizumab-prd-2015-06
